AbstractRenal amyloidosis is one of the most severe complications of familial Mediterranean fever (FMF). Colchicine has reduced the incidence of this complication, which now only appears in untreated, under-treated and resistant patients, but it is usually ineffective in patients with advanced amyloidosis. Here we report a patient with FMF and biopsy-proven amyloidosis who presented with nephrotic syndrome despite colchicine treatment. Anakinra (an interleukin-1β inhibitor) was started and a dramatic complete remission of nephrotic syndrome was observed in the following months. Anakinra can be an effective treatment for FMF patients with severe secondary amyloidosis
Tumor necrosis factor receptor associated periodic syndrome (TRAPS) is a rare monogenic autoinflamma...
Colchicine-induced rhabdomyolysis following a concomitant use of clarithromycin in a haemodialysis p...
WOS: 000354611700011PubMed ID: 25760087Familial Mediterranean fever (FMF) is the most common heredit...
AbstractRenal amyloidosis is one of the most severe complications of familial Mediterranean fever (F...
Background. Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder, ...
ResumenLa amiloidosis renal es una de las complicaciones más graves de la fiebre mediterránea famili...
Familial Mediterranean fever (FMF) is an autosomal reces-sive disease characterized by recurrent epi...
in a renal transplantation patient: successful treatment with anakinra Background Familial Mediterra...
Familial Mediterranean Fever (FMF) is the most prevalent monogenic hereditary autoinflammatory disea...
Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory disease, is manifes...
Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of bo...
Familial Mediterranean fever (FMF) is associated with mutations in the gene coding for pyrin which l...
ABSTRACT BACKGROUND: Up to 5% of familial Mediterranean fever (FMF) cases are unresponsive to colc...
Familial Mediterranean fever (FMF) is a recessive, autosomal, auto-inflammatory disorder characteris...
Familial Mediterranean fever (FMF) is a recessive, autosomal, auto-inflammatory disorder characteris...
Tumor necrosis factor receptor associated periodic syndrome (TRAPS) is a rare monogenic autoinflamma...
Colchicine-induced rhabdomyolysis following a concomitant use of clarithromycin in a haemodialysis p...
WOS: 000354611700011PubMed ID: 25760087Familial Mediterranean fever (FMF) is the most common heredit...
AbstractRenal amyloidosis is one of the most severe complications of familial Mediterranean fever (F...
Background. Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder, ...
ResumenLa amiloidosis renal es una de las complicaciones más graves de la fiebre mediterránea famili...
Familial Mediterranean fever (FMF) is an autosomal reces-sive disease characterized by recurrent epi...
in a renal transplantation patient: successful treatment with anakinra Background Familial Mediterra...
Familial Mediterranean Fever (FMF) is the most prevalent monogenic hereditary autoinflammatory disea...
Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory disease, is manifes...
Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of bo...
Familial Mediterranean fever (FMF) is associated with mutations in the gene coding for pyrin which l...
ABSTRACT BACKGROUND: Up to 5% of familial Mediterranean fever (FMF) cases are unresponsive to colc...
Familial Mediterranean fever (FMF) is a recessive, autosomal, auto-inflammatory disorder characteris...
Familial Mediterranean fever (FMF) is a recessive, autosomal, auto-inflammatory disorder characteris...
Tumor necrosis factor receptor associated periodic syndrome (TRAPS) is a rare monogenic autoinflamma...
Colchicine-induced rhabdomyolysis following a concomitant use of clarithromycin in a haemodialysis p...
WOS: 000354611700011PubMed ID: 25760087Familial Mediterranean fever (FMF) is the most common heredit...